Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debra Patt

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2017
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast CancerMaura N Dickler, Sara M Tolaney, Hope S Rugo, et al.
The Oncologist|May 8, 2013
Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reportingScott D Ramsey, Sean D Sullivan, Shelby D Reed, et al.
JCO Oncology Practice|July 28, 2021
Telehealth in Oncology: ASCO Standards and Practice RecommendationsRobin T Zon, Erin B Kennedy, Kerin Adelson, et al.
Breast Cancer Research and Treatment|August 14, 2020
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1Hope S Rugo, Veronique Dieras, Javier Cortes, et al.
Journal of the American Medical Informatics Association : JAMIA|September 5, 2020
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarityNathan D Seligson, Jeremy L Warner, William S Dalton, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2023
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trialFrankie A Holmes, Beverly Moy, Suzette Delaloge, et al.
The New England Journal of Medicine|February 9, 2022
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Rebecca Dent, et al.
Clinical Breast Cancer|November 13, 2020
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET TrialArlene Chan, Beverly Moy, Janine Mansi, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2017
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast CancerMaura N Dickler, Sara M Tolaney, Hope S Rugo, et al.
The Oncologist|May 8, 2013
Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reportingScott D Ramsey, Sean D Sullivan, Shelby D Reed, et al.
JCO Oncology Practice|July 28, 2021
Telehealth in Oncology: ASCO Standards and Practice RecommendationsRobin T Zon, Erin B Kennedy, Kerin Adelson, et al.
Breast Cancer Research and Treatment|August 14, 2020
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1Hope S Rugo, Veronique Dieras, Javier Cortes, et al.
Journal of the American Medical Informatics Association : JAMIA|September 5, 2020
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarityNathan D Seligson, Jeremy L Warner, William S Dalton, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2023
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trialFrankie A Holmes, Beverly Moy, Suzette Delaloge, et al.
The New England Journal of Medicine|February 9, 2022
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Rebecca Dent, et al.
Clinical Breast Cancer|November 13, 2020
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET TrialArlene Chan, Beverly Moy, Janine Mansi, et al.
Pageof 6